IceCure Medical Secures $2 Million Bridge Loan from Epoch

Icecure Medical ( (ICCM) ) has provided an update.

On May 17, 2025, IceCure Medical Ltd. secured a $2 million bridge loan from Epoch Partner Investments Limited. This financial move is expected to provide the company with necessary funds to support its business activities. The loan agreement includes provisions for early repayment and conditions related to potential equity fundraising, indicating a strategic financial maneuver to enhance operational flexibility and stakeholder engagement.

The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall score reflects its ongoing financial and profitability challenges, balanced by positive sales growth and potential regulatory catalysts. Key strengths include sales momentum and FDA panel support, while high net losses and cash flow issues remain significant concerns.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical Ltd. operates in the medical technology industry, focusing on developing minimally invasive cryoablation therapies for the treatment of cancerous and benign tumors.

Average Trading Volume: 270,135

Technical Sentiment Signal: Sell

Current Market Cap: $57.98M

For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.